In Brief: Centocor's ReoPro

Executive Summary

Centocor's ReoPro: Phase III study in patients scheduled for angioplasty due to refractory unstable angina will be continued after interim data analysis and recommendation by independent safety and efficacy review committee, Centocor and partner Lilly announce. The CAPTURE (Chimeric 7e3 Antiplatelet in Unstable Angina Refractory to Standard Therapy) trial is being conducted in Europe. The antiplatelet MAb abciximab was approved in the U.S. Dec. 22 for treatment of patients undergoing PTCA who are at high risk for abrupt artery closure...